BidaskClub Upgrades Editas Medicine (NASDAQ:EDIT) to “Hold”

Share on StockTwits

Editas Medicine (NASDAQ:EDIT) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports.

Other research analysts have also recently issued reports about the company. Oppenheimer lowered their price objective on 2U from $83.00 to $67.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Evercore ISI began coverage on Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective for the company. Chardan Capital set a $55.00 price objective on Editas Medicine and gave the stock a “buy” rating in a research report on Sunday, June 16th. Finally, Zacks Investment Research raised Garrett Motion from a “sell” rating to a “hold” rating in a research report on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Editas Medicine currently has an average rating of “Buy” and a consensus target price of $37.80.

NASDAQ:EDIT opened at $24.85 on Friday. The business’s 50-day simple moving average is $22.62. The firm has a market cap of $1.22 billion, a PE ratio of -10.67 and a beta of 2.53. Editas Medicine has a 1 year low of $17.80 and a 1 year high of $38.30. The company has a current ratio of 8.46, a quick ratio of 8.46 and a debt-to-equity ratio of 0.07.

Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.03). The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $7.62 million. Editas Medicine had a negative return on equity of 47.64% and a negative net margin of 359.93%. The company’s revenue was down 47.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.67) earnings per share. As a group, research analysts forecast that Editas Medicine will post -2.52 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. boosted its position in shares of Editas Medicine by 398.7% in the 1st quarter. Winslow Evans & Crocker Inc. now owns 1,576 shares of the company’s stock valued at $40,000 after purchasing an additional 1,260 shares during the period. Joseph P. Lucia & Associates LLC acquired a new stake in shares of Editas Medicine in the 1st quarter valued at about $65,000. Bronfman E.L. Rothschild L.P. boosted its position in shares of Editas Medicine by 48.7% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 3,055 shares of the company’s stock valued at $70,000 after purchasing an additional 1,000 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Editas Medicine in the 4th quarter valued at about $109,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Editas Medicine by 10.4% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,697 shares of the company’s stock valued at $139,000 after purchasing an additional 537 shares during the period. 75.43% of the stock is owned by hedge funds and other institutional investors.

About Editas Medicine

Editas Medicine, Inc operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas.

Further Reading: Cash Asset Ratio

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Slack  Earns Neutral Rating from Analysts at Credit Suisse Group
Slack Earns Neutral Rating from Analysts at Credit Suisse Group
Slack  Coverage Initiated by Analysts at Morgan Stanley
Slack Coverage Initiated by Analysts at Morgan Stanley
Solaris Oilfield Infrastructure  Coverage Initiated by Analysts at Citigroup
Solaris Oilfield Infrastructure Coverage Initiated by Analysts at Citigroup
Tanger Factory Outlet Centers  Upgraded to “Hold” at Zacks Investment Research
Tanger Factory Outlet Centers Upgraded to “Hold” at Zacks Investment Research
Sterling Bancorp  Coverage Initiated at B. Riley
Sterling Bancorp Coverage Initiated at B. Riley
Restoration Hardware  Upgraded by ValuEngine to “Hold”
Restoration Hardware Upgraded by ValuEngine to “Hold”


© 2006-2019 Ticker Report